|Day Low/High||170.56 / 174.31|
|52 Wk Low/High||141.38 / 285.75|
Potential leaders are out there, but volume levels are less than desirable.
Alexion Pharma is too far above established support to be considered a buy at this point, so wait for a pullback closer to this key level.
These stocks, which outperformed during the summer crash, should continue to outperform in the near future.
While the stock has been under steady selling pressure, this key level has seen continuous buying interest.
Stamps.com (Nasdaq:STMP) is trading at unusually high volume Monday with 559,950 shares changing hands. It is currently at four times its average daily volume and trading up $1.72 (+8.8%).
Stamps.com (Nasdaq:STMP) hit a new 52-week high Friday as it is currently trading at $20.19, above its previous 52-week high of $19.95 with 187,560 shares traded as of 11:10 a.m. ET. Average volume has been 138,500 shares over the past 30 days.
Risk remains ever-present, but I was able to weather this pullback well.
Shares of Stamps.com (Nasdaq:STMP) were gapping up Friday morning with an open price 15.1% higher than Thursday's closing price. The stock closed at $13.68 yesterday and opened today's trading at $15.75.
Stamps.com CEO Discusses Q2 2011 Results - Earnings Call Transcript
Stamps.com (Nasdaq:STMP) has been upgraded by TheStreet Ratings from a hold to buy.
Stamps.com CEO Discusses Q1 2011 - Earnings Call Transcript
Stamps.com (Nasdaq:STMP) has been downgraded by TheStreet Ratings from from a buy to hold.
Shares of Stamps.com (Nasdaq:STMP) were gapping up Friday morning with an open price 13.5% higher than Thursday closing price. The stock closed at $12.76 yesterday and opened today's trading at $14.48.
Stamps.com CEO Discusses Q4 2010 Results - Earnings Call Transcript
Stamps.com CEO Discusses Q3 2010 Results â¿¿ Earnings Call Transcript
Trinity Industries, Capitol Federal Financial, Ingram Micro, Southwest Casino upgraded; O'Reilly Automotive downgraded.
Sector stocks advance, though several big movers head down on earnings news.
Shares of InSite Vision rise on reports of a patent agreement with Pfizer.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.